Active — Not RecruitingNot Applicable

A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

Spain200 participantsStarted 2023-06-14

Plain-language summary

The purpose of the study is to collect clinical data on the persistence with ozanimod treatment, as well as to describe its effects on participant-relevant outcome parameters in treatment-naïve participants with RRMS.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Relapsing-remitting multiple sclerosis (RRMS) diagnosis by 2017 revised McDonald criteria at the treatment start * Participant who started treatment with ozanimod for the first time 3 months (+/- 2 weeks) before inclusion, according to European Union (EU) Summary of Product Characteristics (SmPC) and/or Spanish therapeutic positioning report (TPR) recommendation and following routine clinical practice of the participating hospital * Low-to-moderate activity, defined as less than 2 relapses in the previous year before starting the treatment with ozanimod Exclusion Criteria: * Prior exposure to ozanimod or any other disease modifier treatment (DMT) for RRMS before starting treatment with ozanimod subject of this study * Participant who has started ozanimod within a clinical trial Note: Other protocol-defined inclusion/exclusion criteria apply

What they're measuring

Time from ozanimod treatment initiation to ozanimod treatment permanent discontinuation

Timeframe: Up to 24 months

Percentage of participants on treatment with ozanimod at 24 months

Timeframe: At month 24

Trial details

NCT IDNCT05811416

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-11-09

View on ClinicalTrials.gov More Relapsing-remitting Multiple Sclerosis (RRMS) trials